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ABSTRACT 
Pharmaceutical corporations face rapidly rising process research and development (R&D) as well as 
production costs due to globalised competition.  Batch production processes are dominant in the 
pharmaceutical industry and have multiple advantages, including equipment flexibility, high-fidelity 
quality control and the ability to recall specific batches; they however suffer disadvantages such as 
limited heat transfer and mixing scalability and low operational asset efficiency.  Continuous 
Pharmaceutical Manufacturing (CPM) has a documented potential to reduce cost because continuous 
production techniques can be easier to scale up and can be designed to be more efficient in terms of 
both solvent and energy use: therefore, it is both timely and important to explore the expanding 
feasibility limits of this emerging technology.  The literature has been extensively surveyed in order to 
identify a series of candidate Active Pharmaceutical Ingredients (API) for flowsheet synthesis, 
process modelling and mass balance simulation toward rapid assessment of CPM potential.  Ibuprofen 
[2-(4-isobutylphenyl)propanoic acid], the widely used non-steroidal anti-inflammatory drug (NSAID), 
has emerged as an ideal CPM candidate because it is in high global demand and can generate 
significant profit margins.  The flowsheet is based on a published organic synthesis pathway and 
produces 50 kg of ibuprofen annually using three plug flow reactors (PFRs) in series, followed by a 
final separation for purification.  Kinetic and thermodynamic parameter estimation modelling has 
been employed in order to compute essential data for design, and all PFR reactors have been designed 
based on reported conversions of feed and intermediate organic molecules in the respective 
pharmaceutical synthesis reactions.  Theoretically computed reactor designs are in good agreement 
with experimental prototypes constructed for the same organic synthesis, as well as in with previously 
reported CPM systems. The developed continuous final separation performs very well in accordance 
with green chemistry principles, and with relatively low environmental impact (an E-factor of 25.4). 
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1 INTRODUCTION 
Batch manufacturing processes feature advantages including equipment usage versatility, flexible 
production planning and scheduling, and a wide range of attainable products, and have dominated the 
pharmaceutical industry for a number of decades;  they still are considerably more preferable due to 
regulatory and licensing considerations and the option to quickly recall specific batches of products 
(Plumb, 2005).  Nevertheless, they have several disadvantages: new processes are often difficult to 
scale up to production level due to poor heat transfer and mixing (potentially resulting in unacceptable 
product quality) and efficiency can be very low with high volumes of unrecovered solvent (Anderson, 
2012; Gernaey et al., 2012).  Batch production plants also require significant intermediate storage 
capacity between process stages, resulting in large inventories of feedstock organic chemicals and 
sensitive intermediates. 
In recent years, pharmaceutical firms have faced mounting pressure to reduce ever-increasing R&D 
as well as production costs (Fig. 1).  The commercialisation of new drugs can require up to $1.8 
billion in total per product, a high cost which has been steadily increasing (Fig. 2).  Competition from 
generic drug manufacturers also increases the pressure on pharmaceutical firms (Behr et al., 2004).  
Taking into account clinical approval and patent duration, by the time the product reaches the market 
half of its patent life may have expired; once this occurs, the original developer may lose up to 90% of 
market share to generic manufacturers (Plumb, 2005). 
Continuous Pharmaceutical Manufacturing (CPM) offers many advantages: lower costs, reduced 
waste, decreased time-to-market for new drugs, continuous flow reactors can deliver significantly 
higher yields, and solvent and energy waste can be decreased by up to 90% by steady-state operation 
(Kockmann et al., 2008; Roberge et al., 2008; Anderson, 2012).  For identical production rates, 
continuous systems require considerably smaller equipment volumes than batch processes (Ashe and 
Lazowski, 2012).  Lower solvent requirement and more efficient heat transfer during exothermic 
reactions both lead to safer operation (LaPorte and Wang, 2007; Kockmann et al., 2008; Roberge et 
al., 2008), therefore CPM can offer cost savings to pharmaceutical corporations, as it does in 
commodity and fine chemicals industries (Schaber et al., 2011).  Labour cost can also be reduced, due 
to the limited need for human intervention in material transport and quality control (Plumb, 2005). 
Experimental demonstration and process validation at pilot plant scale are key to showcasing CPM 
benefits: as this is laborious, costly and time-consuming, flowsheet synthesis and process modelling 
can be used to investigate the feasibility and viability of candidate CPM processes (Douglas, 1988; 
Gerogiorgis and Barton, 2009).  Minimal investment is required, and numerous process options and 
configurations can be rapidly evaluated by means of suitable mathematical models and simulations, 
especially when pilot plants are expensive and know-how is limited (Gerogiorgis and Ydstie, 2005). 
This work presents an adapted flowsheet and a steady-state process model which has been 
developed for the continuous synthesis and purification of an Active Pharmaceutical Ingredient (API) 
identified as a promising candidate for this new production paradigm.  Reactor design has been 
performed based on published kinetics of the continuous organic synthesis pathway, and a final 
separation stage for product purification has been designed, with multiple solvents evaluated with 
respect to API recovery and green chemistry performance.  Process modelling and simulation have 
thus been successfully applied to illustrate the benefits and feasibility of CPM for ibuprofen. 
The paper is organized as follows: the evaluation of candidate APIs is presented, and following this 
the static model flowsheet and mass balances are shown.  Published data is analysed to determine 
reaction orders and kinetic constants, which are then used to design continuous plug flow reactors.  A 
summary of material properties is given next, followed by heat transfer requirements and final 
separation design.  Finally, mass balance and unit operation design results are discussed in relation to 
the technical feasibility of the process and the emerging field of CPM process R&D.  Detailed kinetic, 
thermodynamic and physicochemical property prediction models are presented in the Appendix. 
2 
2 API SELECTION 
2.1 Identification of candidate APIs 
An API is the biologically active chemical species of a pharmaceutical drug (the remainder being 
composed of inert material, the excipient).  Although there is a multitude of APIs in commercially 
available formulations today, not all are amenable to continuous manufacturing.  To identify suitable 
CPM candidates, the literature has been extensively surveyed in order to identify published organic 
flow synthesis pathways. 
The following candidates have been identified: artemisinin, casein-kinase 1 (CK1) inhibitor, 
vitamin D3, diphenhydramine, δ-opioid receptor (DOR) agonists, (R)-flurbiprofen, ibuprofen, 
imatinib, taurine- and glycine-conjugated ursodeoxycholic acid (TUDCA and GUDCA), and reflux 
inhibitor AZD6906. 
Artemisinin has well-known anti-malarial properties and is extensively used in traditional Chinese 
medicine.  First extracted from the sweet wormwood plant Artemisia annua in 1972, artemisinin and 
its derivatives are the fastest-acting antimalarial drugs available today (Tu, 2011).  The current 
Fig. 1. R&D expenditure of the pharmaceutical industry vs. other UK sectors (Office for National Statistics, 2011). 
 
Fig. 2. Cost of new pharmaceutical product R&D and commercialisation (Morgan et al., 2011).  
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3 
production method relies on plant cultivation and subsequent extraction (White, 2008); the continuous 
production of artemisinin from the waste product of this extraction process has been recently 
demonstrated (Kopetzki et al., 2013).  This method converts dihydroartemisinic acid (DHAA) into 
artemisinin, and construction of a scaled-up system with an annual capacity of one metric tonne is 
currently under way (Kopetzki et al., 2013). 
Casein-kinase 1 (CK1) inhibitor is potent in the regulation of mammal circadian rhythms, and 
research indicates it is promising for the regulation of sleep disorders and mood disorders (Lee et al., 
2009).  Recently, Sanofi-Aventis developed a class of CK1 inhibitors, and certain ones have been 
synthesised continuously (Almario et al., 2009). 
Vitamin D3 has extreme physiological importance, as this molecule and its analogues are used to 
treat osteoporosis and renal failure (Posner and Kahraman, 2003).  A continuous route for the 
synthesis of activated vitamin D3 and some of its analogues has been reported (Fuse et al., 2012). 
Diphenhydramine, discovered in 1942, is a first-generation antihistamine first marketed as 
Benadryl® (Ravina and Kubinyi, 2011).  More effective than many newer antihistamines at treating 
allergic symptoms, it also has sedative properties and is used in sleep aids (Richardson et al., 2002).  
Global demand of diphenhydramine is high (at over 100 metric tonnes a year), and recent work has 
demonstrated its continuous flow synthesis using molten ionic salts (Snead and Jamison, 2013). 
DOR agonists have been shown to have analgaesic properties without the side-effects associated 
with opioids; recently, researchers have presented a continuous synthesis method for the production a  
DOR (developed by Astra Zeneca) and some of its analogues (Wei et al., 2000; Qian et al., 2010). 
Flurbiprofen is a non-steroidal anti-inflammatory drug (NSAID) used to treat several pathological 
conditions, including osteoarthritis.  The R-enantiomer of flurbiprofen, R-flurbiprofen, has undergone 
clinical trials for a variety of conditions (Wechter et al., 2000; Quann et al., 2007), and a continuous 
synthesis pathway and isolation method of R-flurbiprofen has been reported (Tambornini et al., 2012). 
Ibuprofen [2-(4-isobutylphenyl)propanoic acid] is a widely used NSAID which treats pain, fever, 
and inflammation, and is listed as essential by the World Health Organisation.  The original 6-step 
synthesis devised in the 1960s has been replaced by a more efficient 3-step method (Adams, 1992).  A 
continuous synthesis pathway for ibuprofen has been published recently (Bogdan et al., 2009). 
Imatinib is effective in treatment of multiple cancers, especially chronic myeloid leukaemia 
(Goldman and Melo, 2003).  Marketed as Glivec®, it has been highly successful commercially (with 
revenues of $4.7 billion in 2012) and commands one of the highest prices for an anti-cancer treatment 
at $92,000 a year (Abboud et al., 2013).  A continuous production method has been developed as well 
in order to handle poorly soluble intermediates (Hopkin et al., 2010). 
Ursodeoxycholic acid (UDCA) is a secondary bile acid which can be conjugated with amino-acids 
(e.g. taurine and glycine) to form TUDCA and GUDCA, with potential therapeutic uses in stroke, 
Parkinson’s, and Huntington’s diseases (Rivard et al., 2007; Boatright et al., 2009).  A continuous 
flow synthesis pathway has also been reported for the conjugation of UDCA with taurine and glycine 
at the multi-gram scale (Venturoni et al., 2012). 
Reflux inhibitor AZD6906 is a promising API without central nervous system side-effects.  
However, its batch synthesis is difficult due to highly exothermic reactions, toxic reagents, and 
unstable products; consequently, researchers have developed a continuous process which adapts a 
previous batch synthesis route (Gustafsson et al., 2012). 
2.2 Evaluation of candidate APIs 
The identified candidate APIs require systematic evaluation: technical as well as economic 
considerations have been taken into account and ten (10) broad criteria have been defined in order to 
comparatively rank the candidates and determine which API would be the most attractive to pursue 
for flowsheet synthesis, process modelling and simulation. 
A.  Is the process fully continuous? One of the driving forces for CPM is the need to overcome 
drawbacks such as batch process intermediate storage and scheduling, which result in low operational 
asset efficiency.  A fully continuous process is more desirable than one with even one batch unit 
operation (typically a separation or purification). 
B.  Is the final product a currently marketed API?  Economic evaluation is of high importance for 
CPM development.  The business case for a continuous flow process is stronger if the API is 
commercially available, because this implies a clear scope for revenue and cost reduction. 
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C.  Is the process of low to medium complexity?  The feasibility and viability of complex CPM 
pathways are subject to higher uncertainties, so processes which require fewer and/or conventional 
unit operations and configurations are more preferable. 
D.  Has the process been implemented?  Evidence of actual or planned CPM implementation 
(either at pilot-plant or production level) strengthens the likelihood of success. 
E.  Are feedstock and reagent materials readily available?  The availability of feedstocks and 
reagents is key to feasibility: processes which rely on chemicals which are prohibitively expensive (or 
whose supply cannot be guaranteed) are less favourable for implementation. 
F.  Does the continuous synthesis pathway offer improved performance over the batch process?  
A promising API synthesis method must demonstrate clear advantages over current batch production 
processes. 
G.  Can the process be scaled up easily and safely?  A CPM route must be feasible at a pilot plant 
as well as production level in order to realise the expected benefits over batch production. 
H.  Are intermediate separations eliminated?  The most attractive process has a minimal number 
of intermediate separations (excluding final purification), which imply lower solvent and energy use. 
I.  How high is the price of the commercially available product?  The business case (and 
profitability) of a CPM process is stronger if the final API is sold at a high price. 
J.  How high is the global sales volume?  If the product API is in high global demand, the business 
case for a CPM process will be stronger. 
The identified candidate APIs have been graded using a scale of 0 to 5: here, 0 indicates that the 
criterion is not at all being satisfied and 5 indicates that it is satisfied completely.  The complete 
qualitative analysis and the final API ranking are presented in Table 1. 
Ibuprofen emerges as the most promising candidate API.  Both artemisinin and diphenhydramine 
are both widely marketed APIs and thus strong candidates; however, there is limited data on the raw 
material for artemisinin, while CPM of diphenhydramine relies on the use of molten ionic salts (Snead 
and Jamison, 2013).  Imatinib commands a high price, but its continuous synthesis is complex and 
requires batch separations (Hopkin et al., 2013).  The remaining candidates are less commercially 
significant, require batch processes, or do not satisfy one or more of the other foregoing criteria. 
3  FLOWSHEET AND PROCESS MODELLING 
The flowsheet considered here is an adaptation of a published continuous flow organic synthesis 
which relies on a series of three plug flow reactors (PFRs) in series for the production of ibuprofen 
(Bogdan et al., 2009).  The complete reaction scheme is illustrated in Fig. 3. 
Isobutylbenzene (IBB) is mixed with propanoic acid.  The resulting stream is then mixed with neat 
triflic acid (TfOH, an acid catalyst) and the mixture enters the first reactor, operated at 150 °C: IBB 
undergoes Friedel-Crafts acylation to produce 1-(4-isobutylphenyl)propan-1-one (intermediate 2), and 
the reactor outlet stream is cooled to 0 °C. 
Table 1.  Systematic evaluation of candidate APIs for CPM. 
 
API Candidate 
Selection Criteria   
A B C D E F G H I J Score Rank
Ibuprofen 5 5 4 2 4 4 3 5 2 5 39 1
Diphenhydramine 5 5 5 1 4 4 2 5 3 4 38 2
Artemisinin 3 5 3 5 2 4 4 3 4 4 37 3
TUDCA/GUDCA 3 1 4 2 3 3 3 2 1 1 33 4
Activated vitamin D3 5 4 3 0 1 2 4 5 3 3 30 5
Imatinib 2 5 1 0 2 4 2 0 5 5 26 6
R-flurbiprofen 5 1 4 0 2 4 4 2 0 0 22 7
AZD6906 0 0 2 0 4 4 4 4 0 0 18 8
CK1 inhibitor 4 0 2 0 3 3 3 1 0 0 16 9
DOR agonist 2 0 2 0 3 3 3 0 0 0 13 10
5 
Diacetoxyiodobenzene, PhI(OAc)2, is dissolved with trimethyl orthoformate (TMOF) in methanol 
(MeOH).  The resulting stream is cooled to 0 °C before mixing with the cooled first reactor product. 
The combined stream is fed into the second reactor, where intermediate 2 undergoes PhI(OAc)2-
mediated 1,2-aryl migration to produce methyl 2-(4-isobutylphenyl)propanoate (intermediate 3), with 
TfOH again acting as acid catalyst.  The second reactor is operated at 50 °C: its product is mixed with 
potassium hydroxide (KOH) dissolved in a methanol-water mixture and fed into the third reactor. 
In the third reactor, intermediate 3 is saponified (base-hydrolysed) to the salt form of ibuprofen, 
and a series of batch operations has been previously used to separate and purify ibuprofen: the 15-step 
batch process consists of quenching, extraction, crystallisation and filtration operations, and must be 
replaced by a continuous final separation.  An important mass balance assumption is that the product 
of the third reactor is entirely acidified to obtain a potassium-free acid form of ibuprofen, as the salt 
obtained from the third reaction is unsuitable for pharmaceutical formulations (Bogdan et al., 2009). 
The continuous organic synthesis and purification flowsheet considered here is illustrated in Fig. 4. 
Reaction 1 
 
+ 
 
																						
 
 
 
+ H2O 
IBB + C2H5COOH 2 + H2O 
Reaction 2 
 
+ 
 
+ 
 
+ H2O 												
										
 
 
2 + PhI(OAc)2 + TMOF + H2O 
 
 
+ 
 
+ 
 
+ 
 
+ 
 
3 + PhI + 2AcOH + MeOH + HCOOCH3 
Reaction 3 
 
+ KOH 
																												
 
 
 
+ 
 
3 + KOH API (salt) + MeOH 
Fig. 3. Reaction stoichiometries and by-products.  Reaction 1: Friedel-Crafts acylation in PFR 1.  Reaction 2: 
PhI(OAc)2-mediated 1,2-aryl migration in PFR 2.  Reaction 3: base hydrolysis in PFR 3 (Bogdan et al., 2009). 
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3.1 Mass balance calculations 
Performing PFR reactor design requires the calculation of the process mass balances (Table 2-3).  The 
starting point is a recent synthesis study (Bogdan et al., 2009), with the following assumptions: 
- Reactions occur only inside the PFR reactors and not in any of the lines connecting them. 
- The conversion of intermediate 3 to K-ibuprofen in the third reactor can reach 99%. 
- Isothermal operation is ensured in all reactors via suitable heating media and thermostats. 
- Temperature changes cause no phase transformation or precipitation affecting the flow. 
- Esterification reactions between methanol and all organic acids encountered are negligible. 
- Reactions between unreacted reagents/by-products and subsequent chemicals are negligible. 
- The API salt (K-ibuprofen) is entirely acidified with a suitable acid prior to the final separation. 
4 KINETIC PARAMETER ESTIMATION 
The determination of the order of all three reactions and the calculation of reaction rate constants is 
essential for efficient CPM design. Bogdan et al. (2009) have published kinetic data for the first two 
continuous organic synthesis reactions.  Reaction orders and rate constants have been computed here 
by evaluating several candidate kinetic expressions, plotting functions of concentrations against time 
and calculating the corresponding coefficients of determination (R2) for each case considered (Fig. 5).  
For the first reaction (Friedel-Crafts acylation), experimental data is given for varying residence time 
(5, 10, 20 minutes), reaction temperature (50, 100, 150 ºC), and equivalents of propanoic (1.0, 1.1 and 
1.5) and triflic acid (4.0 and 5.0).  A second-order reaction is the most plausible case (R2 = 0.836, 
compared to R2 = 0.721 for zero order and R2 = 0.776 for first order) and the reaction rate constant has 
been calculated as k1 = 31.41 L mol 1  hr 1  (at T = 150 ºC), with 1.1 and 5.0 equivalents of propanoic 
acid and TfOH, respectively. Complex kinetic models would imply multi-stage reaction mechanisms.
 
Fig. 4. Conceptual flowsheet for continuous production of ibuprofen (adapted from Bogdan et al., 2009). 
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For the second reaction [PhI(OAc)2-mediated 1,2-aryl migration], experimental data has also been 
analysed for varying residence time (1 and 2 minutes), temperature (35 ºC, 50 ºC, and 60 ºC), and 
excesses of TfOH (3.0 and 5.0 equivalents) and TMOF (2.0, 4.0 and 9.0 equivalents).  In their 
evaluation of optimum reaction conditions they use propiophenone (PEK) in place of intermediate 2, 
with the stated assumption that the results are applicable to 2 on the basis of molecular similarity.  
From data analysis (Fig. 5), the most plausible case is again a second-order reaction (R2 = 0.978, 
compared to R2 = 0.733 for zero order and R2 = 0.926 for first order), and the reaction rate constant 
has been calculated as k2 = 2732 L mol1 hr 1  (at T = 50 ºC), with 5.0 and 4.0 equivalents of TfOH and 
TMOF, respectively.  Kinetic parameter estimation equations and details are given in the Appendix. 
For the third reaction (API salt production), empirical data is not available; therefore, a predictive 
tool for physical properties and chemical reactivity of organic molecules (SPARC) has been used to 
estimate k3, the reaction rate constant for the base hydrolysis reaction (Hilal and Karickhoff, 2003).  
The feed stream of the third reactor (F20) contains mainly water and methanol (ca. 80% vol.), a fact 
which justifies our assumption that (for the purpose of reaction rate estimation only) these are the only 
two solvents considered present, in their actual volume ratios (16.57% and 83.43%, respectively). For 
the operating temperature of the third reactor (65 °C), the reaction rate constant k3 has been estimated 
as 15.57 L mol1  hr 1 . Guidelines on SPARC model implementation are available by its developers. 
Table 3. Component molar and mass flow changes due to all three continuous flow reactions. 
 
Component Stoichiometric 
coefficient 
Flow in  Flow change          Flow out 
(mmol hr  1) (g hr  1) (mmol hr  1) (g hr  1) (mmol hr  1) (g hr  1)
PFR 1       
IBB  1 43.52 5.84  39.60  5.31 3.91 0.52
2 +1 0 0 +39.60 +7.53 39.60 7.53
C2H5COOH 1 43.52 3.22 39.60 2.93 3.91 0.29
H2O +1 0 0 +39.60 +0.71 39.60 0.71
TfOH   216.62 32.51     216.62 32.51
PFR 2       
IBB  3.91 0.52   3.91 0.52
2 1 39.60 7.53 38.82 7.38 0.78 0.15
3 +1 0 0 +38.82 +8.55 38.82 8.55
C2H5COOH   3.91 0.29     3.91 0.29
H2O 1 39.60 0.71 38.82 0.69 0.78 0.01
TfOH  216.62 32.51   216.62 32.51
PhI(OAc)2 1 44.19 14.23 38.82 12.50 5.37 1.73
TMOF  1 174.32 18.49  38.82  4.11 135.49 14.37
MeOH +1 1294.12 41.46 +38.82 +1.24 1332.95 42.70
HCOOCH3 +1 0 0 +38.82 +2.33 38.82 2.33
AcOH +2 0 0 +77.65 +4.66 77.65 4.66
PhI +1 0 0 +38.82 +7.91 38.82 7.91
PFR 3       
IBB   3.91 0.52   3.91 0.52
2   0.78 0.15   0.78 0.15
3 1 38.82 8.55 38.37 8.46 0.44 0.08
API (salt) +1 0 0 +38.37 +9.39 38.37 9.39
C2H5COOK   3.91 0.43   3.91 0.43
H2O   1969.27 35.48   1969.27 35.48
TfOK   216.62 40.76   216.62 40.76
PhI(OAc)2   5.37 1.73     5.37 1.73
TMOF   135.49 14.37     135.49 14.37
MeOH +1 4308.24 138.03 +38.37 +1.23 4346.62 139.26
HCOOCH3   38.82 2.33   38.82 2.33
AcOK   77.65 7.61     77.65 7.61
PhI   38.82 7.91   38.82 7.91
KOH 1 872.74 48.96 38.37 2.15 834.37 46.81
5 PLUG FLOW REACTOR (PFR) DESIGN 
Reactor design is performed assuming ideal solutions, homogeneous mixtures, no radial concentration 
gradients, and isothermal operation without axial or radial temperature gradients: specific heat 
capacities and reaction enthalpies remain constant within each PFR, and phase changes do not occur.  
All reactors are assumed to be submerged in heating media with adequate flow circulation; due to the 
small radial size considered, heat transfer suffices so as to ensure constant and uniform temperature.   
The first reaction is assumed to be second-order (first in IBB and first in propanoic acid), the 
second reaction is also assumed to be second-order (first order in intermediate 2 and first order in 
PhI(OAc)2), and the third reaction is assumed to be pseudo-first-order (first-order in intermediate 3 
due to a considerable excess of potassium hydroxide used for the base hydrolysis). These assumptions 
are justified by the kinetic parameter estimation and model reactions with the highest possible fidelity. 
The standard plug flow reactor performance equation has been used: 
∫
−
=
fAX
A
A
Ai
r
dXC ,
00,
τ  (1) 
Published data indicate that 91% conversion is achievable in the first reactor, and that over 98% is 
attainable in the second one (Bogdan et al., 2009).  No data has been published for the conversion of 
the base hydrolysi in the third reactor, for which a value of 99% has been assumed.  The assumptions 
that have been made and the parameters estimated toward PFR design are summarised in Table 4. 
 
Fig. 5. Reaction order and kinetic parameter determination.  A:  reaction 1 (feed concentrations: CIBB,0 = 1.42 M, 
CC2H5COOH,0 = 1.56 M).  B: reaction 2 (feed concentrations: CPEK,0 = 0.38 M, CPhI(OAc)2,0 = 0.39 M). 
Table 4. Plug Flow Reactor (PFR) design basis and assumptions. 
 
 PFR 1 PFR 2 PFR 3 
Reaction 1 2 3 
Reaction order  2 2 2 
Reaction type Friedel-Crafts acylation 1,2-aryl migration Base hydrolysis 
Rate law COOHHCIBBIBB CCkr 521=−  2)(222 OAcPhICCkr =− 33 Ckr ′=−  
Reactor temperature (°C) 150 50 65 
Conversion (%) 91 98 99 
Rate constant ki (L mol 1 hr 1) 31.41 2732.3 15.57 
Coefficient of determination (R2) 0.836 0.978 – 
Method for ki Data analysis Data analysis SPARC model 
R² = 0.836
0.0
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6 MATERIAL PROPERTIES 
Thermodynamic and physical properties of certain organic compounds in the CPM flowsheet are not 
available in the literature and thus require estimation by reliable property modelling methods. The 
compilation of published data and property modelling estimates conducted is summarised in Table 5. 
Reactor heating duties (for feed heating as well as maintaining prescribed operating temperatures) 
require accurate estimation of reaction enthalpies, which in tured can be computed using the standard 
formation enthalpies of chemical compounds, and specific heat capacities under constant pressure. 
For intermediates 2 and 3, ibuprofen, PhI(OAc)2, methyl formate (HCOOCH3), and acetic acid 
(AcOH), standard formation enthalpies have been calculated using a group contribution method 
(Constantinou and Gani, 1994): 
∑∑ +=−°
j
jj
i
iiff hMhNhH∆ 210  (2)
Here, h1i is the contribution of first-order group i, and Ni is the number of occurrences of h1i . 
Similarly, h2j is the contribution of second-order group j, and Mi is the number of occurrences of h2j .  
The constant value hf 0 = 10.835 kJ mol-1 is universal, and tabulated h1i and h2j values are available. 
The specific heat capacity under constant pressure (CP) has been computed via the Shomate 
equation for water, IBB, propanoic acid, and potassium hydroxide, using the polynomial coefficients 
A, B, C, D and E which are available in the NIST-JANAF Thermochemical Tables (Chase, 1998): 
2
32
T
EDTCTBTACP ++++=  (3)
The specific heat capacity under constant pressure of all other molecules (for which data is not 
available) has been computed via a group contribution method (Rihani and Doraiswamy, 1965): 
∑ ∑∑∑ +++=
i i
iiii
i
ii
i
iiP TdnTcnTbnanC
32
 (4)
Here ni  is the number of occurrences of functional group i within the molecule, ai, bi, ci and di are 
tabulated literature values associated with group i, and T is the absolute temperature (K). 
Table 5. Physical properties of CPM flowsheet stream components.  
a: Chase, 1998; b: Rihani and Doraiswamy, 1965; c: Constantinou and Gani, 1994; d: published data. 
 
Component MW (g mol 1 ) 
Density 
(g cm3 ) 
Melting point 
(°C) 
Boiling point 
(°C) 
CP (T = 25 ºC) 
(kJ mol1  K1 ) 
∆°Hf 
(kJ mol1 ) 
IBB 134.22 0.844 51.7 170.9 242.79 a 69.9 d 
2 190.29 0.960 18.4 248.8 242.76b 139.9 c 
3 220.31 1.100 38.3 287.0 264.95b 313.6 c 
Ibuprofen (API) 206.29 1.030 74.5 157.0 278.98b 350.3 c 
C2H5COOH 74.08 0.990 21.2 140.9 158.59 b 510.4 d 
H2O 18.02 1.000 0.0 100.0 75.37a 285.8 d 
TfOH 150.08 1.708 40.0 161.9 110.53 b n.r. 
PhI(OAc)2 322.10 1.814 162.5 456.8 200.16b 628.1 c 
TMOF 106.12 0.970 53.0 102.8 136.50 b 586.9 d 
MeOH 32.04 0.792 97.2 64.9 81.42 d 239.0 d 
HCOOCH3 60.05 0.980 100.0 32.0 93.65 b 367.9 c 
AcOH 60.05 1.049 16.5 118.0 66.58b 442.2 c 
PhI 204.01 1.850 31.4 188.0 95.05 b 234.0d 
KOH 56.11 1.050 406.0 1327.0 64.89a 482.4 d 
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Chemical solubilities have been computed using the UNIFAC group contribution method 
(Fredenslund et al., 1975), via activity coefficients which are sums of a combinatorial and a residual 
component.  The prerequisite enthalpies of fusion have also been calculated via a group contribution 
method (Chickos and Acree, 1999). All property estimation equations are presented in the Appendix. 
7 HEAT TRANSFER DESIGN 
Energy balance calculation is essential for process R&D and CPM evaluation: therein, heat transfer 
duty constitutes the dominant energy requirement, since process streams require heating or cooling, 
while reactor operating temperatures must be maintained constant for maximum process efficiency. 
All three plug flow reactors are assumed isothermal (PFR 1: 150 °C, PFR 2: 50 °C, PFR 3: 65 °C). 
Reactor and process lines are considered submerged in heat transfer media with adequate circulation, 
and heat transfer dominates over ancillary (e.g. pumping) requirements in this conceptual flowsheet. 
Reactor heating duty calculations require reaction enthalpy values at corresponding temperatures; 
these have been computed using the reaction enthalpies at standard state, which in turn emerge from 
standard enthalpies of formation of the reagents and products for the respective chemical reactions: 
∑∑ °°° −= reagentsfproductsfrxn ∆H∆H∆H ,,  (5)
Reaction enthalpies at the corresponding reactor temperatures are calculated using Hess’s Law, 
considering the sum of three terms: the enthalpy change in cooling the reactants from the constant 
reactor temperature T to standard temperature (° = 25 °C), the reaction enthalpy at standard state, 
and the enthalpy change in heating the products from 25 °C to the reactor operating temperature: 
( ) ( )∑∑ °−++−°= ° TTC∆HTTC∆H productsPrxnreagentsPrxn ,,  (6)
The heating duty for each reactor is thus computed as a sum of feed heating and reaction enthalpy. 
For temperatures above the boiling points of certain components (e.g. methanol, methyl formate), 
empirical observations indicate that partial evaporation (off-gassing) is possible (Bogdan et al., 2009). 
Nevertheless, this process simulation study assumes that all components remain in the liquid phase 
throughout the flowsheet and off-gassing is negligible by suitable reactor design (Mascia et al., 2013). 
8 FINAL SEPARATION DESIGN 
Development of continuous separation and purification unit operations is critical in order to attain the 
full potential of CPM. Product streams frequently contain large quantities of excess reagent to be 
recycled, and by-products which must be removed; moreover, an aqueous product (API) stream (e.g. 
via continuous solvent exchange) is essential in downstream processing and final dosage formation. 
A Pfizer solvent selection guide classifies solvents as preferred, usable or undesirable, based on 
their environmental impact (Alfonsi et al., 2008): accordingly, a selection of solvents from all three 
categories has been evaluated, including ethanol and ethyl acetate (preferred), toluene and acetonitrile 
(usable), and hexane (undesirable) and methyl acetate (unclassified). Water and methanol (preferred) 
are both present in the process, as they are essential according to the organic synthesis considered. 
The API potassium salt form dissolved in stream F21 cannot be used in commercial formulations, 
due to its extreme hygroscopicity which compromises stability (Gruber, 2009).  Before purification, 
stream F21 is assumed entirely acidified so that all ibuprofen is in its formal (carboxylic acid) form.  
The composition of the remainder of stream F21 has been assumed unchanged after this acidification 
step (the conversion of API salt to carboxylic acid form does not affect other effluent components). 
The product stream of the third reactor must undergo final API purification. An efficient choice for 
this continuous API separation from an organic stream is liquid-liquid extraction (LLE): therein, the 
introduction of a new solvent (in which the valuable API solute exhibits preferentially high solubility) 
induces a multiphase mixture, as long as it is partially or entirely immiscible with the original solvent. 
For LLE design, stream F21 is assumed a binary mixture of water and methanol with several solutes. 
Ternary phase diagrams have been used to calculated compositions upon solvent addition and phase 
separation (Skrzecz et al., 1999) at ambient and effluent operating temperatures (25 °C and 65 °C). 
Thermodynamic equilibrium between the aqueous and the organic phase is rapidly established in the 
LLE unit, and no crystallisation or precipitation is considered to occur under these flow conditions. 
The API distribution in each of the two (organic/O and water/W) phases relies on the assumption that 
the partition coefficient of ibuprofen is equal to the ratio of corresponding solubilities in each phase; 
these are computed for each of the resulting (O, W) phases via the UNIFAC method (cf. Appendix). 
9 RESULTS AND DISCUSSION 
9.1 Mass balance 
The continuous system presented here produces 9.39 g hr 1  (72.6 kg annually for 46 weeks of 
operation) of potassium ibuprofen, which corresponds to 61.3 kg of ibuprofen annually after 
acidification and prior to recovery.  The computed plantwide mass balance relies on experimental 
conversions (Bogdan et al., 2009), and a graphic summary of four key streams is illustrated in Fig. 6. 
The main organic solvents are methanol (MeOH), and triflic acid (TfOH): the former is the primary 
carrier solvent of reagents (but also a minor by-product) of the second and third reactors (Figs. 3-4) 
and forms 45.4% (139.3 g hr–1) of the reactor effluent stream (F21) which is fed to final purification. 
The latter occurs in most streams (Table 2) and serves as acid catalyst in the first two reactors (Fig. 3). 
The majority of streams are hence predominantly organic, but water is also a critical component of the 
solvent mixture (stream F15) which is essential for the base hydrolysis in the third reactor (Fig. 4).   
Apart from key organic molecules (IBB, intermediates 2 and 3, and ibuprofen in salt form), 
significant quantities of unreacted reagents and by-products remain in solution, often due to the need 
  
  
Fig. 6.  Mass balance of key flowsheet streams (g hr  1). 
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to use reagents in excess (e.g. TMOF, HCOOCH3, KOH).  This is particularly important in stream 
F21, where unreacted reagents and by-products form 92.9% of the dissolved chemical substances, 
implying a clear need for a final separation ensuring API purification before downstream processing. 
9.2 Reactor design 
The reactor sizes computed (PFR 1: 6.392 mL, PFR 2: 1.997 mL, PFR 3: = 28.912 mL) (Table 7) are 
reasonably small for the target capacity, illustrating the CPM benefit of space-efficient equipment. 
The reactors have been designed with a relatively small internal diameter (ID = 5.0 mm) to ensure 
efficient heat transfer; CPM pilot plant systems have been successfully demonstrated at this scale, 
with heat transfer ID = 1.6 mm and reactor ID = 11.7 to 40 mm, respectively (Mascia et al., 2013). 
Process simulations have also been performed at the reported capacity and compared to the published 
reactor dimensions implemented in the laboratory-scale experimental system (Bogdan et al., 2009).  
Computed reactor volumes are similar; the third reactor estimate is larger than that reported, implying 
a SPARC underestimation of the base hydrolysis rate constant (k3) due to the lack of kinetic data. 
9.3 Heat transfer design 
Continuous synthesis reactions are endothermic: enthalpies at PFR temperatures are given in Table 7. 
Inlet streams to all three reactors require energy to reach and be kept at the operating temperature.  
The computed reactor heating requirements are of the same order of magnitude, but the wide variation 
in reactor lengths induces a considerably lower specific heating duty for the third reactor (Table 7). 
Energy duties have been computed solely for preheating feeds and maintaining isothermal operation: 
pumping, cooling, losses and power for Process Analytical Technology (PAT) are not considered, but 
heat integration opportunities must be taken into account in the detailed design phase for CPM plants. 
9.4 Final separation design 
Six organic solvents (ethanol, acetonitrile, toluene, n-hexane, ethyl acetate, methyl acetate) have been 
evaluated as LLE candidates; the first five are discussed in a Pfizer publication (Alfonsi et al., 2008). 
Ethanol and acetonitrile are fully miscible with stream F21, yielding no manageable phase separation. 
System compositions obtained for LLE using methyl/ethyl acetate are outside the multiphase region 
for all levels of solvent use in both temperatures considered, so miscibility renders them unsuitable. 
Ternary equilibrium phase diagrams for likely solvents (toluene and n-hexane) are given in Fig. 7.  
The solubility of ibuprofen in the resulting immiscible phases has been calculated for each solvent 
mixture and each operating temperature via the UNIFAC method; results are summarised in Table 8.  
The solubilities reported here are considerably higher in case of high-temperature operation at 65 °C.  
Calculated ibuprofen solubilities for pure solvents (methanol, toluene, n-hexane; very poor in water) 
have been validated and are in very good agreement with previous data (Gracin and Rasmuson, 2002).  
Ibuprofen saturation is never approached in this design, so the focus is on ratios of phase solubilities.  
Table 6. PFR design results. 
a: Bogdan et al. (2009); b: assumption. 
 
PFR # 
 
Temperature 
(°C) 
Flowrate
 
(mg hr 1 ) 
Conversion 
(%) 
Internal diameter, ID 
(mm) 
Volume 
(mL) 
Length 
(mm) 
PFR 1 150 41.58 91a 5.0 6.392 326 
PFR 2 50 115.77 98a 5.0 1.997 102 
PFR 3 65 306.90 99b 5.0 28.912 1472 
Table 7. PFR heating: energy requirements. 
 
PFR #   
 
Reaction Length 
(mm) 
ID 
(mm) 
Tfeed 
(°C) 
∆Hrxn TPFR 
(°C) 
Flowrate in
 
Duty Power 
(kJ mol 1) (mg hr  1) (mol hr  1) (W cm 1 PFR) (W) 
PFR 1 Endothermic 326 5.0 25 143.0 150 41.58 0.304 0.103 3.361 
PFR 2 Endothermic 102 5.0 0 54.2 50 115.77 1.816 0.299 3.042 
PFR 3 Endothermic 1472 5.0 50 207.5 65 306.90 7.710 0.033 4.852 
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The performance of each solvent has been evaluated by considering API solubility and distribution 
for a wide range of solvent-to-feed mass ratios (0.25 to 5), at two key temperatures (25 °C and 65 °C).  
API recovery is higher at ambient temperature (25 °C) for n-hexane, and at higher (65 °C) for toluene. 
Ambient operation better illustrates the scope of CPM and its inherent green chemistry potential, as 
the option to operate purification separations without high energy requirement is certainly desirable. 
Hexane performs best for the lowest solvent-to-feed ratio (0.25) at ambient LLE operation (25 °C), 
achieving the highest API recovery of 97.4% at the expense of close proximity to the equilibrium line. 
For a more practical solvent-to-feed ratio (0.5), API recovery remains over 89% at both temperatures.  
Toluene achieves a marginally to clearly lower API recovery than hexane, at ambient temperature.  
Nonetheless, the use of toluene is preferable as it is a classified usable solvent of safe performance, 
while n-hexane is classified as undesirable due to its high environmental impact (Alfonsi et al., 2008). 
The lower solvent-to-feed ratios that are feasible for hexane (0.25, 0.5) are not operable for toluene, as 
they yield a perfectly miscible mixture which cannot induce the necessary phase separation for LLE. 
However, the minimum feasible solvent-to-feed ratio considered in simulations (0.75) still achieves 
acceptably high API recovery, which reaches 81.7% and 89.2% at 25 °C and 65 °C, respectively. 
Ambient operation (25 °C) is recommended as more energy-efficient: it avoids the LLE heating cost 
and the reported possibility of partial evaporation (which is even more likely at larger scale), thus 
achieving an annual production of 50.0 kg of ibuprofen (assuming 46 weeks of plant operation). 
 
T = 25 °C Toluene (C7H8)      T = 65 °C 
  
T = 25 °C n-Hexane (C6H14)       T = 65 °C 
  
Fig. 7.  Ternary phase diagrams for water-methanol-solvent (H2O-MeOH-S) systems at both temperatures. 
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The environmental (E-) factor is a widely used green chemistry metric with a versatile definition 
(Sheldon, 2012):  in its simplest form, it is the waste mass generated per unit mass or product, so 
lower E-factor values are more desirable and indicate greener design. Ranging widely, it is typically 
0.1 in petrochemical industries, but can be as high as 200 for pharmaceutical products (Ritter, 2013).  
The E-factor is computed as a mass ratio of waste (all material not recovered) to API (ibuprofen):  
API
waste
m
mE =  (7)
uAPIusurbpdwaste mmmm +++=  (8)
E-factors have been calculated considering a downstream solvent (methanol and toluene/n-hexane) 
recovery of 90% (Sheldon, 2012), API recovery as reported, and remaining waste comprising all by-
products, unreacted feed, 10% waste solvents and un-recovered API. Results are given in Table 8.  
The solvent feed obviously affects the effluent masses of unrecovered API and solvent waste, both of 
which in turn have a strong impact on the E-factor, as indicated by Eq. (8); this is particularly evident 
in case of the highest solvent-to-feed ratio (5), where the E-factor is larger by an order of magnitude.   
Toluene is the recommended LLE solvent when considering green chemistry but also performance: 
for a solvent-to-feed ratio of 0.75 at ambient temperature (25 °C), its use yields an E-factor of 25.4.  
This is actually a quite acceptable value, rather low for the purpose of pharmaceutical manufacturing, 
and much lower than E-factors of many pharmaceuticals produced by batch methods (Sheldon, 2012). 
10 CONCLUSIONS 
This paper presents a steady-state process model and simulation for the continuous production of a 
selected API which has emerged after systematic evaluation of several technical and market criteria. 
Continuous plug flow reactors and the final purification have been designed for CPM of ibuprofen, 
via systematic kinetic parameter estimation, solvent selection and thermodynamic property modelling, 
which is imperative for most organic molecules. Green design efficiency is explored via the E-factor.  
Reaction order determination and kinetic parameter estimation have been performed by analysing 
published data of a continuous flow synthesis pathway (Bogdan et al., 2009). Three plug flow reactors 
in series have been designed: the computed PFR volumes (6.4, 2.0, 28.9 mL) are relatively small and 
clearly illustrate the fixed cost and plant footprint advantages of continuous over batch manufacturing. 
Energy requirements for ensuring high endothermic conversions under isothermal reactor operation 
are also quite reasonable and imply high potential for energy efficiency, justifying the expectation of 
fixed as well as operating cost advantages of CPM over batch manufacturing (Schaber et al., 2011). 
Actual CPM energy requirements will be slightly higher, due to auxiliary (e.g. pumping) functions. 
 Design of a continuous final separation step after the third reactor is essential for a CPM process, to 
obtain an aqueous API stream which is pure enough to be fed to secondary (downstream) processing.  
A systematic evaluation of several candidate organic solvents (via UNIFAC solubility estimation) 
indicates that toluene is the most efficient extraction solvent, achieving a 81.7% ibuprofen recovery at 
a solvent-to-feed mass ratio of 0.75 and ambient temperature (25°C), yielding 50.0 kg API annually.  
This systematic LLE separation design achieves high API recovery with low solvent requirement, 
thus demonstrating the green chemistry principles of solvent and waste minimisation: a widely used 
environmental impact metric (the E-factor) has been computed for all candidate designs, and the value 
corresponding to the selected design (25.4) is quite low compared to many pharmaceutical processes.  
Ibuprofen hereby emerges as an ideal API for Continuous Pharmaceutical Manufacturing (CPM): 
this therapeutic molecule is in high global demand and its production has extreme societal importance, 
thus representing a significant business opportunity for pilot- and production-scale implementations.  
The small PFR volumes and heating duties computed illustrate the documented (Roberge et al., 2008) 
and realised (Mascia et al., 2013) advantages of CPM technology, while the final LLE separation and 
reasonable solvent duty showcase the potential to design inherently green pharmaceutical processes. 
The suitability of methanol and a solvent exchange to ethanol (the de facto batch processing solvent) 
require more investigation, to facilitate the integration of CPM with downstream processing practice. 
The concurrent need for model-based technical and economic optimisation of the entire CPM process 
also emerges clearly by this process simulation study and must be pursued with systematic methods. 
17 
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NOMENCLATURE 
Latin Letters 
A Shomate equation parameter 
ai Heat capacity group contribution estimation parameter for functional group i 
as Pure solid component activity  
B Shomate equation parameter 
bi Heat capacity group contribution estimation parameter for functional group i 
C Shomate equation parameter 
CA Concentration of molecule A, mol L1  
CA,0 Initial concentration of molecule A, mol L1   
Ci Group coefficient for functional group i in the total phase change entropy group additivity 
estimation method 
CP Specific heat capacity at constant pressure, J mol1  K1  
ci Heat capacity group contribution estimation parameter for functional group i 
D Shomate equation parameter 
di Heat capacity group contribution estimation parameter for functional group i 
E Shomate equation parameter 
Gi Contribution from one functional group i to the total phase change entropy in the group 
additivity estimation method, J mol-1 K-1 
hf 0 Constant used in estimating the standard enthalpy of formation ∆°Hf 
h1i  Standard enthalpy of formation group contribution of a single first-order group i   
h2j  Standard enthalpy of formation group contribution of a single second-order group j  
ID Internal diameter, mm 
k’ Pseudo-first-order reaction rate constant, s1 
ki Rate constant of reaction i, L mol1  s1  (second-order reaction) 
Li UNIFAC compound parameter of r, q and z  
Mj Number of j second-order functional groups 
mAPI Mass of recovered API 
mbpd Mass of byproducts 
mur Mass of unreacted reagents 
mus Mass of unrecovered solvent 
muAPI Mass of unrecovered API 
MW Molecular weight, g mol 1 
mwaste Mass of waste 
Ni Number of i first-order functional groups 
2CHn  Number of consecutive CH2 groups 
ni  Number of i functional groups 
Qk UNIFAC surface area parameter for functional group k  
qi UNIFAC parameter for molecule i , a measure of Van der Waals molecular surface area 
R Universal gas constant, 8.3144 J mol 1  K1  
R2 Coefficient of determination  
Rk UNIFAC volume parameter for functional group k  
rA Rate of reaction of molecule A, mol l 1  s1 
ri UNIFAC parameter for molecule i , a measure of Van der Waals volume 
T Temperature, K 
T° Standard temperature, 298 K 
Tfeed Feed temperature, °C 
TPFR Reactor temperature, °C 
Tfus Melting (fusion) point temperature, K 
18 
t Time, hr 
Umn UNIFAC energy interaction between groups m and n  
XA Conversion of molecule A at time t  
XA,f Final conversion of molecule A  
xi Mole fraction of molecule i 
xm UNIFAC mole fraction of group m 
xi 
sat
 Mole fraction at saturation (solubility) 
z UNIFAC system coordination number (default value: 10) 
Greek Letters 
Γk UNIFAC residual group activity coefficient for group k  
Γk
(i)
 UNIFAC residual group activity coefficient in a reference solution of 100% i molecules 
γi Activity coefficient of component i 
γi 
c
 UNIFAC combinatorial component of    
γi 
r
 UNIFAC residual component of   
γi 
sat
 Activity coefficient of component i at saturation 
∆°Hf Standard enthalpy of formation, J mol 1 
∆Hfus Enthalpy of fusion, J mol 1 
∆°Hrxn Standard reaction enthalpy, J mol 1 
∆Hrxn Reaction enthalpy, J mol1 
tpce
T
m H∆ fus  Total phase change enthalpy, J mol
-1 
∆Sfus Entropy of fusion, J mol1  K1  
tpce
T S∆ fus0  Total phase change entropy, J mol
1
 K1  
θi UNIFAC molar-weighted area fractional component for molecule i  
θm UNIFAC summation of area fraction of group m over all different groups  
νk 
(i)
 UNIFAC number of occurrences of functional group k in molecule i 
τi Residence time in reactor i, hr 
ϕi UNIFAC molar-weighted segment fractional component molecule i 
Ψmn UNIFAC group energy interaction parameter 
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APPENDIX 
A1. Reaction kinetics 
The differential rate equation for a second order reaction between two substances A and B (first order 
in A as well as in B) is written with respect to reactant A as follows: 
BA
A CkC
dt
dC
=−  
(A1)
The following nonlinear equation is obtained by integration: 
( )tCCk
CC
CC
AB
BA
AB
0,0,
0,
0,ln −=
 (A2)
A plot of 
0,
0,ln
BA
AB
CC
CC
  against time results in a linear correlation, given that the initial concentrations 
of the reactants ( 0,AC and 0,BC ) are generally not equal.  The reaction rate constant k can be 
determined from the slope of the plot, which is equal to ( )tCCk AB 0,0, − . 
For the first PFR, the reaction rate equation for the key organic feedstock (IBB) is: 
COOHCHCHIBBIBB CCkr 231=−  (A3)
This can be written as: 
21 
( )( )IBBIBBCOOHHCIBBIBBIBB XCCXCCkr 0,0,0,0,11 52 −−=−  (A4)
The integral form is used to evaluate the required residence time and reactor volume: 
( )( )∫ −−= fIBB
X
IBBIBBCOOHHCIBBIBBIBB
IBBIBB
IBB XCCXCC
dX
k
C ,
52
0 0,0,0,0,2
0,τ  (A5)
For the second PFR, the reaction rate equation for organic intermediate 2 is: 
2)(222 OAcPhICCkr =−  (A6)
Organic intermediate 2 and PhI(OAc)2 react in a 1:1 stoichiometric ratio, however the feed is not 
equimolar: 
( )( )20,20,)(20,20,222 2 XCCXCCkr OAcPhI −−=−  (A7)
The integral form is again used to evaluate the required residence time and reactor volume: 
( )( )∫ −−= f
X
OAcPhI XCCXCC
dX
k
C ,2
2
0 20,20,)(20,20,2
2
2
0,2
2τ  (A8)
For the third PFR, the reaction rate equation is: 
−
=− OHCCkr 333  (A9)
Potassium hydroxide (KOH) is in excess, so this is a pseudo-first order reaction rate equation: 
33 Ckr ′=−  (A10)
where the pseudo-first order reaction constant kꞌ is: 
−
=′ OHCkk 3  (A11)
The integrated form is used to evaluate the required residence time and reactor volume:  
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A2. Enthalpy of fusion 
The total phase change entropy tpce
T S∆ fus0  is considered a valid approximation for the entropy of 
fusion ( fus∆S ) and is estimated using equation (A27) for aliphatic and benzenoid aromatic 
hydrocarbons: 
fustpce
T
∆SS∆ fus ≅0  (A13)
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Parameter Gi indicates a group and its associated additivity value, and ni is the number of 
occurrences of Gi.  Group coefficients Ci are used (i.e. ni Gi Ci) where there are multiple occurrences, 
with the exception of methylene (CH2) groups, where the group coefficient value is 1.31 if the number 
of consecutive CH2 groups exceeds the number of other groups and 1.0 otherwise.  The calculation 
requires tabulated values of Gi and Ci (Chickos and Acree, 1999). 
With tpce
T S∆ fus0  taken to be a good estimate of the entropy of fusion, the total phase change enthalpy 
tpce
T
m H∆ fus is estimated as follows (assuming no additional solid phase changes): 
fustpce
T
tpce
T
m TS∆H∆ fusfus 0=  
(A16) 
The total phase change enthalpy is similarly considered a valid approximation of the enthalpy of 
fusion, fus∆H : 
tpce
T
mfus H∆∆H
fus≅  
(A17)
A3. Solubility 
The UNIFAC activity coefficient for molecule i ( iγ ) is the sum of a combinatorial ( ciγ ) and a residual 
component ( riγ ) (Fredenslund et al., 1975): 
r
i
c
ii γγγ lnlnln +=  (A18)
The combinatorial component is calculated via the UNIQUAC model (Abrams and Prausnitz, 1975): 
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(A19) 
where iφ  and iθ  are the molar weighted segment (similar to volume) and area fractional components, 
respectively.  Furthermore, Li is a UNIFAC compound parameter defined by ri , qi and z: 
∑
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Parameters ir  and iq  are calculated from contributions of R  and Q  (the volume and surface area 
parameters for each functional group, respectively) according to their occurrence kν  on the molecule: 
( )∑=
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The residual component is calculated as follows: 
( ) ( )[ ]∑ Γ−Γ=
k
i
kk
i
k
r
i lnlnln νγ  (A25)
where kΓ  and ( )ikΓ  is the residual group activity coefficient of group k in reality and in a reference 
solution of pure substance i, respectively. Both kΓ  and ( )ikΓ  are calculated via the following equation: 
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where parameters mθ  (summation of the area fraction of group m over all different groups) and xm 
(the mole fraction of group m) are defined as follows: 
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(A28) 
Parameter mnΨ  is calculated using a modified Arrhenius equation and represents a measure of 
interaction energy between groups: 


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Ψ nmmnmn exp  (A29)
Tabulated data for values of Q, R and group interactions have been published for a multitude of 
groups (Wittig et al., 2003). 
The solubility (mole fraction at saturation satix ) of components in solvent mixtures is calculated 
using the following equation (Gracin et al., 2002): 
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Here, Hfus is the enthalpy of fusion and Tfus is the melting point of pure solid solute i.  The solid 
activity ( sia ) is first estimated via the exponential of Eq. (A30), and the activity coefficient obtained 
from Eq. (A18) is used to obtain the solubility of the solid in the solvent mixture ( satix ) via Eq. (A30).  
An iterative process is required for Eq. (A30), as the activity coefficient depends on mole fraction. 
